TITLE

Synergen lineage may finally pay off

AUTHOR(S)
Alper, Joseph
PUB. DATE
March 1999
SOURCE
Nature Biotechnology;Mar1999, Vol. 17 Issue 3, p217
SOURCE TYPE
Academic Journal
DOC. TYPE
Article
ABSTRACT
Reports on the business performance of Boulder, Colorado-based Array BioPharma Inc. as of March 1999. Corporate background of Array; Business strategies adopted by Array to generate income in the short term; Analysts' assessment of Array's business strategies.
ACCESSION #
8820320

 

Related Articles

  • ARRAY BIOPHARMA REPORTS 3RD QTR NET LOSS OF 14 MILLION.  // Biotech Financial Reports;Jun2007, Vol. 14 Issue 6, p3 

    The article reports that Array Biopharma Inc., a biopharmaceutical company, has revealed net loss of $14 million in financial assets for the third quarter of fiscal 2007 in Boulder, Colorado. Array's revenue has decreased from $11.7 million in 2006 to $10.4 million in 2007. The revenue results...

  • CLINIC ROUNDUP.  // BioWorld Today;6/21/2007, Vol. 18 Issue 120, p6 

    This section offers news briefs related to the pharmaceutical industry. Alexza Pharmaceuticals Inc. has begun a Phase IIa proof-of-concept trial with AZ-104 in patients with migraine headache. Altus Pharmaceuticals Inc. presented an investigational new drug application for ALTU- 237, a...

  • CLINIC ROUND UP.  // BioWorld Today;8/6/2007, Vol. 18 Issue 151, p5 

    The article reports on clinical trials initiated by several pharmaceutical companies. Array BioPharma Inc. filed an investigational new drug application with the FDA for ARRY-380. Hana Biosciences has initiated a multicenter Phase II clinical trial of Marqibo in adult patients. ImmunoCellular...

  • ALLIANCE/COLLABORATIONS.  // Drug Discovery & Development;Feb2002, Vol. 5 Issue 2, p28 

    Reports several strategic alliances and collaborations in the pharmaceutical industry. Agreement between Neurotech S.A. and Amgen Inc.; Initiation of a drug discovery Amgen Inc. and Array BioPharma Inc.; Collaboration between PIERES Proteolab AG and CytoTools GmbH.

  • Takeda and Array BioPharma Enter Drug Discovery Pact.  // Chemical Market Reporter;4/12/2004, Vol. 265 Issue 15, p2 

    Reports on Takeda Chemical Industries Ltd.'s signing of a second drug discovery deal with Boulder, Colorado-based Array BioPharma Inc. to develop small-molecule drug candidates against a Takeda target.

  • Active Pharmaceuticals Ingredient Watch.  // Chemical Market Reporter;1/21/2002, Vol. 261 Issue 3, p14 

    Presents an update on the pharmaceutical industry as of January 21, 2002. Sales growth posted by Abbott Laboratories Inc. in 2001; Series of nonexclusive agreements signed by Array Biopharma Inc.; Joint venture company established by Bachem Ltd. and Berna Biotech.

  • CLINIC ROUNDUP.  // BioWorld Today;11/21/2007, Vol. 18 Issue 227, p2 

    This section offers news briefs in the pharmaceutical industry. Dosing of its small-molecule p38 inhibitor ARRY-797 has been commenced by Array Biopharma Inc. in a Phase II trial to evaluate its efficacy for pain in dental patients undergoing third molar extraction. Data has been reported by...

  • Celgene Pays Array $40M In Drug Discovery Deal.  // Bioworld Week;10/1/2007, Vol. 15 Issue 40, p3 

    The article discusses the payments received by Array BioPharma Inc. in Boulder, Colorado which values at $40 million from Celgene Corp. for a drug discovery deal for cancer and inflammatory disease. According to Array's chief executive officer Robert Conway, the Celgene deal is considered as one...

  • Clinic Roundup.  // BioWorld Today;7/3/2013, Vol. 24 Issue 127, p7 

    This section offers news briefs related to the pharmaceutical industry in the U.S. as of July 2013. Array BioPharma Inc. achieved success in conducting a trial in patients with low-grade serous ovarian cancer (LGSOC). The results of a study on the Alprolix long-lasting clotting factor was...

Share

Read the Article

Courtesy of THE LIBRARY OF VIRGINIA

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics